{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-021876","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2024-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.369779+00:00","generated_at":"2026-05-31T23:42:49.758601+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dyadic licenses fungal platforms to Proliant for recombinant albumin; up to $1.5M milestones + profit share","bullets":["Dyadic and Proliant Health and Biologicals partner to commercialize animal-free recombinant human serum albumin.","Dyadic to receive up to $1.5M in milestone payments plus a share of profits from product sales.","First product launch expected in the first half of 2025, targeting the ~$6B serum albumin market.","Proliant will use Dyadic's fungal microbial expression platforms for production."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-021876","json":"https://secwatch.observer/filing/0001437749-24-021876.json","markdown":"https://secwatch.observer/filing/0001437749-24-021876.md","text":"https://secwatch.observer/filing/0001437749-24-021876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774924021876/0001437749-24-021876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774924021876/dyai20240627_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:42:49.758601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}